Nucleoside transport inhibitors: Structure-activity relationships for pyrimido[5,4-d ]pyrimidine derivatives that potentiate pemetrexed cytotoxicity in the presence of α-1-acid glycoprotein

Journal of Medicinal Chemistry

Volumn 54, Issue 6, 2011, Pages 1847-1859

  Saravanan, Kappusamy ^a   Barlow, Hannah C ^a   Barton, Marion ^a   Calvert, A Hilary ^b   Golding, Bernard T ^a   Newell, David R ^b   Northen, Julian S ^a   Curtin, Nicola J ^b   Thomas, Huw D ^b   Griffin, Roger J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 [[4 [(3,4 DIMETHOXYBENZYL)AMINO] 6 [(2 HYDROXYPROPYL)AMINO] 8 [[3 METHOXY 4 (3 MORPHOLINOETHOXY)BENZYL]AMINO]PYRIMIDO[5,4 D]PYRIMIDINE 2 YL]AMINO]PROPAN 2 YL PHENYLCARBAMATE; 1 [[4 [(3,4 DIMETHOXYBENZYL)AMINO] 8 [(4 HYDROXY 3 METHOXYBENZYL)AMINO] 6 [(2 HYDROXYPROPYL)AMINO]PYRIMIDO[5,4 D]PYRIMIDINE 2 YL]AMINO]PROPAN 2 YL PHENYLCARBAMATE; 1 [[4,8 BIS[(3,4 DIMETHOXYBENZYL)AMINO] 6 [(2 HYDROXYPROPYL)AMINO]PYRIMIDO[5,4 D ]PYRIMIDINE 2 YL]AMINO]PROPAN 2 YL 2 [(TERT BUTOXYCARBONYL)AMINO] 3 METHYLBUTANOATE; 1 [[4,8 BIS[(3,4 DIMETHOXYBENZYL)AMINO] 6 [(2 HYDROXYPROPYL)AMINO]PYRIMIDO[5,4 D ]PYRIMIDINE 2 YL]AMINO]PROPAN 2 YL 2 AMINO 3 METHYLBUTANOATE; 1 [[4,8 BIS[(3,4 DIMETHOXYBENZYL)AMINO] 6 [(2 HYDROXYPROPYL)AMINO]PYRIMIDO[5,4 D]PYRIMIDINE 2 YL]AMINO]PROPAN 2 YL PHENYLCARBAMATE; 1 [[4,8 BIS[(3,4 DIMETHOXYBENZYL)AMINO] 6 [[2 (PHOSPHONOOXY)PROPYL]AMINO]PYRIMIDO[5,4 D]PYRIMIDINE 2 YL]AMINO]PROPAN 2 YL PHENYLCARBAMATE; 1 [[6 [(2,3 DIHYDROXYPROPYL)AMINO] 4,8 BIS[(3,4 DIMETHOXYBENZYL)AMINO]PYRIMIDO[5,4 D]PYRIMIDINE 2 YL]AMINO]PROPAN 2 YL PHENYLCARBAMATE; 1 [[6 [[2 [(2 AMINO 3 METHYLBUTANOYL)OXY]PROPYL]AMINO] 4,8 BIS[(3,4 DIMETHOXYBENZYL)AMINO]PYRIMIDO[5,4 D]PYRIMIDINE 2 YL]AMINO]PROPAN 2YL 2 AMINO 3 METHYLBUTANOATE; 1 [[6 [[2 [(DI TERT BUTOXYPHOSPHORYL)OXY]PROPYL]AMINO] 4,8 BIS[(3,4 DIMETHOXYBENZYL)AMINO]PYRIMIDO[5,4 D]PYRIMIDINE 2 YL]AMINO]PROPAN 2 YL PHENYLCARBAMATE; 4 [[1 [[4,8 BIS[(3,4 DIMETHOXYBENZYL)AMINO] 6 [(2 HYDROXYPROPYL)AMINO]PYRIMIDO[5,4 D]PYRIMIDINE 2 YL]AMINO]PROPAN 2 YL]OXY] 4 OXOBUTANOIC ACID; 4,4' [[[[4,8 BIS[(3,4 DIMETHOXYBENZYL)AMINO]PYRIMIDO[5,4 D]PYRIMIDINE 2,6 DIYL]BIS(AZANEDIYL)]BIS(PROPANE 2,1 DIYL)]BIS(OXY)]BIS(4 OXOBUTANOIC ACID); 4,8 BIS[(3,4 DIMETHOXYBENZYL)AMINO] 2,6 BIS[(2 HYDROXYPROPYL)AMINO]PYRIMIDO[5,4 D]PYRIMIDINE; [[4,8 BIS[(3,4 DIMETHOXYBENZYL)AMINO]PYRIMIDO[5,4 D]PYRIMIDINE 2,6 DIYL]BIS(AZANEDIYL)]BIS(PROPANE 2,1 DIYL)BIS(PHENYLCARBAMATE); [[4,8 BIS[(3,4 DIMETHOXYBENZYL)AMINO]PYRIMIDO[5,4 D]PYRIMIDINE 2,6 DIYL]BIS(AZANEDIYL)]BIS(PROPANE 2,1 DIYL)BIS[2 [(TERT BUTOXYCARBONYL)AMINO] 3 METHYLBUTANOATE]; DIPYRIDAMOLE; NU 3108; OROSOMUCOID; PEMETREXED; PYRIMIDO[5,4 D]PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; STRUCTURE ACTIVITY RELATION;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; DRUG SYNERGISM; GLUTAMATES; GUANINE; HUMANS; NUCLEOSIDES; OROSOMUCOID; PRODRUGS; PROTEIN BINDING; PYRIMIDINES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79952785674     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm101493z     Document Type: Article

References (40)

1. Hyde, R. J.; Cass, C. E.; Young, D. A.; Baldwin, A. E. The ENT family of eukaryotic nucleoside and nucleobase transporters; recent advances in the investigation of structure-function relationships and the identification of novel isoforms Mol. Membr. Biol. 2001, 18, 53-63 (Pubitemid 32521597)
2. King, A. E.; Ackley, M. A.; Cass, C. E.; Young, J. D.; Baldwin, S. A. Nucleoside transporters: from scavengers to novel therapeutic targets Trends Pharmacol. Sci. 2006, 27, 416-425 (Pubitemid 44051567)
3. Rose, J. B.; Coe, I. R. Physiology of nucleoside transporters: back to the future Physioloy 2008, 23, 41-48
4. Buolamwini, J. K. Nucleoside transport inhibitors: structure-activity relationships and potential therapeutic applications Curr. Med. Chem. 1997, 4, 35-66 (Pubitemid 27154393)
5. Walling, J. From methotrexate to pemetrexid and beyond. A review of the pharmacodynamics and clinical properties of antifolates Invest. New Drugs 2006, 24, 37-77 (Pubitemid 43168187)
6. Weber, G. Biochemical strategy of cancer cells and the design of chemotherapy Cancer Res. 1983, 43, 3466-3492
7. Kinsella, A.; Harran, M. S. Decreasing sensitivity to cytotoxic agents agents parallels increasing tumorigenicity in human fibroblasts Cancer Res. 1991, 51, 1855-1859
8. Webber, S.; Bartlett, C. A.; Boritzki, T. J.; Hilliard, J. A.; Howland, E. F.; Johnston, A. L.; Kosa, M.; Margosiak, S. A.; Morse, C. A.; Shetty, B. V. AG337, a novel lipophilic thymidylate synthase inhibitor; in vitro and in vivo preclinical studies Cancer Chemother. Pharmacol. 1996, 37, 509-517 (Pubitemid 26080147)
9. Worzalla, J. F.; Shih, C.; Schultz, R. M. Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate LY23514 Anticancer Res. 1998, 18, 3235-3240
10. Schultz, R. M.; Patel, V. F.; Worzalla, J. F.; Shih, C. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate LY23514 Anticancer Res. 1989, 19, 437-444
11. 8-alkylamine-substituted purines J. Med. Chem. 2005, 48, 321-329 (Pubitemid 40105271)
12. Schaper, W. Dipyridamole, an underestimated vascular protective drug Cardiovasc. Drugs Ther. 2005, 19, 357-363 (Pubitemid 43029821)
13. Van Mouwerik, T. J.; Pangallo, C. A.; Willson, J. K. V.; Fischer, P. H. Augmentation of methotrexate cyttoxicity in human colon cancer cells achieved through inhibition of thymidine salvage by dipyridamole Biochem. Pharmacol. 1987, 36, 809-814 (Pubitemid 17038023)
14. Goel, R; Howell, S. B. Modulation of the activity of cancer chemotherapeutic agents by dipyridamole. In New Drugs Concepts and Results in Cancer Chemotherapy; Muggia, F. M., Ed.; Kluwer Academic Publishers: Boston, 1992; pp 19 - 44.
15. Smith, P. J.; Marshman, E.; Newell, D. R.; Curtin, N. J. Dipyridamole potentiates the in vitro activity of MTA (LY231514) by inhibition of thymidine transport Br. J. Cancer 2000, 82, 924-930 (Pubitemid 30085247)
16. Turner, R. N.; Aherne, G. W.; Curtin, N. J. Selective potentiation of lomotrexol growth inhibition by dipyridamole through cell-specific inhibition of hypoxanthine salvage Br. J. Cancer 1997, 76, 1300-1307 (Pubitemid 27474971)
17. Marshman, E.; Newell, D. R.; Calvert, A. H.; Dickinson, A. M.; Patel, H. R. H.; Campbell, F. C.; Curtin, N. J. Dipyridamole potentiates antipurine antifolate activity in the presence of hypoxanthine in tumor cells but not in normal tissues in vitro Clin. Cancer Res. 1998, 11, 2895-2902 (Pubitemid 28523521)
18. Asoh, K.-I.; Yoshio, S.; Sato, S.-I.; Nogae, I.; Kohno, K.; Kuwano, M. Potentiation of some anticancer agents by dipyridamole against drug-sensitive and drug-resistant cancer cell lines Jpn. J. Cancer Res. 1990, 80, 475-481 (Pubitemid 20038139)
19. Curtin, N. J.; Harris, A. L.; Aherne, G. W. Mechanism of cell death following thymidylate synthase inhibition: 2-deoxyuridine-5-triphosphate accumulation, DNA damage and growth inhibition following exposure to CB3717 and dipyridamole Cancer Res. 1991, 51, 2346-2352
20. Passer, B. J.; Cheema, T.; Zhou, B.; Wakimoto, H.; Zaupa1, C.; Razmjoo, M.; Sarte, J.; Wu, S.; Wu, C.; Noah, J. W.; Li, Q.; Buolamwini, J. K.; Yen, Y.; Rabkin, S. D.; Martuza, R. L. Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication Cancer Res. 2010, 70, 3890-3895
21. Mahoney, C.; Wolfram, K. M.; Cocetto, D. M.; Bjornsson, T. D. Dipyridamole kinetics Clin. Pharmacol Ther. 1982, 31, 330-338 (Pubitemid 12125453)
22. Hollinshead, A. C.; Chuang, C.-Y. Evaluation of the relationships of prealbumin components in sera of patients with cancer Natl. Cancer Inst. Monogr. 1978, 49, 187-192 (Pubitemid 9141831)
23. 1-acid glycoprotein: reduced potentiation of quinazoline antifolate (CB3717) cytotoxicity by dipyridamole Biochem. Pharmacol. 1989, 38, 3281-3288 (Pubitemid 19254119)
24. Schmoll, H.-J.; Harstrick, A.; Köhne-Wömpner, C.-H.; Schober, C.; Wilke, H.; Poliwoda, H. Modulation of cytotoxic drug activity by dipyridamole Cancer Treat. Rev. 1990, 17 (Suppl. A) 57-65
25. Marman, M.; Chan, T. C. K.; Cleary, S.; Howell, S. B. Phase I trial of combination therapy of cancer with. N-phosphonacetyl- l -aspartate and dipyridamole Cancer Chemother. Pharmacol. 1987, 19, 80-83 (Pubitemid 17017046)
26. Wilson, J. K. V.; Fischer, P. H.; Remick, S. C.; Tutsch, K. D.; Grem, J. L.; Nieting, L.; Alberti, D.; Bruggink, J.; Trump, D. L. Methotrexate and dipyridamole combination chemotherapy based upon inhibition of nucleoside salvage in humans Cancer Res. 1989, 49, 1866-1870 (Pubitemid 19108418)
27. Budd, G. T.; Jayaraj, A.; Grabowski, D.; Adelstein, D.; Bauer, L.; Boyett, J.; Bukowski, R.; Murthy, S.; Weick, J. Phase I trial of dipyridamole with 5-fluorouracil and folinic acid Cancer Res. 1990, 50, 7206-7211
28. Remick, S. C.; Grem, J. L.; Fischer, P. H.; Tutsch, K. D.; Alberti, D. B.; Nieting, L. M.; Tombes, M. B.; Bruggink, J.; Willson, J. K. V.; Trump, D. L. Phase I trial of 5-fluorouracil and dipyridamole administered by seventy-two-hour concurrent continuous infusion Cancer Res. 1990, 50, 2667-2672 (Pubitemid 20150202)
29. Thomae, K. G. (1959, British Patent 807826 (Chem. Abstr. 1959, 53, 12317e)
30. Thomae, K. G. (1963, German Patent 1151806 (Chem. Abstr. 1964, 60, 2974a).
31. Kaminsky, D.; Lutz, W. B.; Lazarus, S. Some congeners and analogs of dipyridamole J. Med. Chem. 1966, 9, 610-612
32. Lin, W.; Buolamwini, J. K. Synthesis, flow cytometric evaluation, and identification of highly potent dipyridamole analogues as equilibrative nucleoside transporter 1 inhibitors J. Med. Chem. 2007, 50, 3906-3920 (Pubitemid 47292054)
33. 1-acid glycoprotein binding Br. J. Cancer 1999, 80, 1738-1746 (Pubitemid 29389626)
34. 1-acid glycoprotein (AGP) Bioorg. Med. Chem. Lett. 2001, 7, 2105-2113
35. Smith, P. G.; Thomas, H. D.; Barlow, H. C.; Griffin, R. J.; Golding, B. T.; Calvert, A. H.; Newell, D. R.; Curtin, N. J. In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity Clin. Cancer. Res. 2001, 7, 2105-2113 (Pubitemid 32994851)
36. 1-acid glycoprotein (AGP) J. Med. Chem. 2004, 47, 4905-4922 (Pubitemid 39238266)
37. Northen, J. S.; Boyle, F. T.; Clegg, W.; Curtin, N. J.; Edwards, A. J.; Griffin, R. J.; Golding, B. T. Controlled stepwise conversion of 2,4,6,8-tetrachloropyrimido[5,4- d ]pyrimidine into 2,4,6,8-tetrasubstituted pyrimido[5,4- d ]pyrimidines J. Chem. Soc., Perkin Trans. I 2002, 108-115 (Pubitemid 35188263)
38. Thomas, H. D.; Saravanan, K. P.; Wang, L.-Z.; Lin, M.-J.; Northen, J. S.; Barlow, H. C.; Hartness, M.; Newell, D. R.; Griffin, R. J.; Golding, B. T.; Curtin, N. J. Preclinical evaluation of a novel pyrimidopyrimidine for the prevention of nucleoside and nucleobase reversal of antifolate cytotoxicity Mol. Cancer Ther. 2009, 8, 1828-1837
39. Cabral, S.; Leis, S.; Bover, L.; Nembrot, M.; Mordoh, J. Dipyridamole inhibits reversion by thymidine of methotrexate effect and increases drug uptake in Sarcoma 180 cells Proc. Natl. Acad. Sci. U.S.A. 1984, 81, 3200-3203 (Pubitemid 14110706)
40. Worm, J.; Kirkin, A. F.; Dzhandzhugazyan, K. N.; Guldberg, P. Methylation-dependent silencing of the reduced folate carrier gene in inherently methotrexate-resistant human breast cancer cells J. Biol. Chem. 2001, 276, 39990-40000